Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Jun 2026

Abstract excerpt

The rearranged during transfection (RET) gene is a proto-oncogene encoding a receptor tyrosine kinase. RET gene alterations are driver events in various tumors. Pralsetinib and selpercatinib are novel, highly selective RET tyrosine kinase inhibitors (RET-TKIs). They are recommended as priority therapeutic options for RET fusion-positive non-small cell lung cancer (NSCLC) in the Chinese Society of Clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Neutropenia
Share to Piperidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Thymine

Source

Identifiers

PMID: 42161875
DOI: 10.3760/cma.j.cn112152-20260107-00014

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)].PMID 42161875Read ↗

Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeSemantic proximity Read ↗

[Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib].Semantic proximity Read ↗

A comprehensive overview of the relationship between RET gene and tumor occurrenceSemantic proximity Read ↗

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.Semantic proximity Read ↗

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.Semantic proximity Read ↗

Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysisSemantic proximity Read ↗

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read ↗

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read ↗

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read ↗

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.Semantic proximity Read ↗

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.